News & Updates

At moderate-to-heavy levels, drinking confers increased atrial fibrillation (AF) risk even in young people, as shown in a large Korean cohort study.

Adding the oral factor XIa (FXIa) inhibitor asundexian to dual antiplatelet therapy (DAPT) may be a safe and effective oral anticoagulation (OAC) alternative for acute MI patients, findings from the PACIFIC-AMI study suggest.

In the REDUCE-IT STEMI trial, icosapent ethyl (IPE) reduced MI events overall and across an array of MI subtypes in statin-treated patients at increased cardiovascular (CV) risk.

Concerns regarding physical appearance are very common among patients suffering from peripheral vascular malformations (VMs), a new study has found. Harbouring these concerns, in turn, could have negative impacts on patients’ mental health-related quality of life (HRQoL).

The long-term use of evolocumab to lower low-density lipoprotein cholesterol (LDL-C) levels appears safe, with consistently low frequency of adverse events over 8 years and leading to further reductions in cardiovascular events, according to a study.

Percutaneous cutting balloon angioplasty (PCBA) is both effective and well-tolerated in the treatment of hypertensive children and adolescents with recurrent or resistant renal artery stenosis, suggests a recent study.